Editor’s Note
**Editor’s Note:** This article covers the recent launch symposium for Huons Group’s botulinum toxin product, Hutox, held in Hangzhou, China. The event, hosted by local partner IMeik Technology, marks a key step in the product’s market entry and academic engagement.
Huons Group’s HuMeds (CEO Kang Min-jong) and Huons BioPharma (CEO Lee Jung-hee) announced that they held a ‘Hutox’ launch symposium on the 16th at the JW Marriott Hotel in Hangzhou, Zhejiang Province, China. The symposium was hosted by Huons BioPharma’s local Chinese partner, IMeik Technology (IMeik), and featured the official product launch of the botulinum toxin ‘Hutox’ along with an academic exchange program.
Through this symposium, HuMeds and Huons BioPharma aimed to expand contact points with local Chinese medical professionals and industry stakeholders, while enhancing the global recognition of Hutox.
Dr. Kim Gun-woo, director of Cheongdam Cellinic Clinic, attended as a speaker and delivered a lecture on Hutox. He shared insights on global trends in botulinum toxin utilization, practical clinical application directions, and product operation know-how.
Hutox is a cosmetic and therapeutic pharmaceutical product with botulinum toxin as its main ingredient, primarily used for improving glabellar lines and crow’s feet. IMeik secured exclusive import and distribution rights for the botulinum toxin product in the Chinese region (including Macau and Hong Kong) from Huons BioPharma in 2022. Subsequently, in January, it received product approval from China’s National Medical Products Administration (NMPA) for Hutox. At this event, HuMeds leveraged its domestic medical professional network to support speaker invitations and academic event communications for the symposium.